Salicylate

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 51177 Experts worldwide ranked by ideXlab platform

J G Hardin - One of the best experts on this subject based on the ideXlab platform.

  • Symptomatic Salicylate ototoxicity: a useful indicator of serum Salicylate concentration?
    Annals of the rheumatic diseases, 1991
    Co-Authors: J T Halla, S L Atchison, J G Hardin
    Abstract:

    A three phase study was designed to define further the sensitivity and specificity of symptomatic Salicylate ototoxicity (primarily tinnitus) for serum Salicylate concentrations. In phase one 260 patients with osteoarthritis and 112 with rheumatoid arthritis, none taking Salicylates, were interviewed about their ear symptoms. Their responses were not significantly different from those of 134 Salicylate treated patients with rheumatoid arthritis previously reported. In the second phase 56 patients who were taking Salicylates, and who volunteered the complaint of tinnitus, had serum Salicylate concentrations measured while symptomatic, and 30 (54%) had concentrations less than 1.3 mmol/l. Few tolerated an upward Salicylate dose adjustment. For phase three, 94 patients were found to have a Salicylate concentration above 2.2 mmol/l on one or more occasion, and these subjects were interviewed. Fifty two patients (55%) had no tinnitus, and tinnitus correlated with the blood Salicylate concentration in only 28 (30%). Audiological evaluation of most of the symptomatic patients was carried out, and results were abnormal in the majority, even in those patients not reporting tinnitus. Symptomatic Salicylate ototoxicity is too nonspecific and too insensitive to be a useful indicator of serum Salicylate concentration.

J T Halla - One of the best experts on this subject based on the ideXlab platform.

  • Symptomatic Salicylate ototoxicity: a useful indicator of serum Salicylate concentration?
    Annals of the rheumatic diseases, 1991
    Co-Authors: J T Halla, S L Atchison, J G Hardin
    Abstract:

    A three phase study was designed to define further the sensitivity and specificity of symptomatic Salicylate ototoxicity (primarily tinnitus) for serum Salicylate concentrations. In phase one 260 patients with osteoarthritis and 112 with rheumatoid arthritis, none taking Salicylates, were interviewed about their ear symptoms. Their responses were not significantly different from those of 134 Salicylate treated patients with rheumatoid arthritis previously reported. In the second phase 56 patients who were taking Salicylates, and who volunteered the complaint of tinnitus, had serum Salicylate concentrations measured while symptomatic, and 30 (54%) had concentrations less than 1.3 mmol/l. Few tolerated an upward Salicylate dose adjustment. For phase three, 94 patients were found to have a Salicylate concentration above 2.2 mmol/l on one or more occasion, and these subjects were interviewed. Fifty two patients (55%) had no tinnitus, and tinnitus correlated with the blood Salicylate concentration in only 28 (30%). Audiological evaluation of most of the symptomatic patients was carried out, and results were abnormal in the majority, even in those patients not reporting tinnitus. Symptomatic Salicylate ototoxicity is too nonspecific and too insensitive to be a useful indicator of serum Salicylate concentration.

Consolato Sergi - One of the best experts on this subject based on the ideXlab platform.

  • co ingestion of aspirin and acetaminophen promoting fulminant liver failure a critical review of reye syndrome in the current perspective at the dawn of the 21st century
    Clinical and Experimental Pharmacology and Physiology, 2018
    Co-Authors: Deepak Dinakaran, Consolato Sergi
    Abstract:

    In the pediatric population, there is some evidence of possible interaction, synergism, and co-toxicity of aspirin and acetaminophen. The toxicity of Salicylates such as aspirin in this population is well known and documented, specifically in the form of Reye syndrome. The possible toxic synergism with aspirin and acetaminophen, however, is not previously described; though case reports suggest such co-toxicities with low levels of aspirin and other compounds can exist. In vitro studies into mechanistic processes of Salicylate toxicity propose that there are a bi-directional link and potentiation with glutathione (GSH) depletion and Salicylate toxicity. Data may suggest a plausible explanation for Salicylate and acetaminophen toxic synergism. Further studies investigating this potential toxic synergism are warranted. Given the lack of awareness in the clinical community about potential toxic synergism between these relatively common medications, caution is advised in the co-administration of these drugs, particularly in communities using natural or alternative therapy. This article is protected by copyright. All rights reserved.

Robert G. Hendrickson - One of the best experts on this subject based on the ideXlab platform.

Barry J. Cusack - One of the best experts on this subject based on the ideXlab platform.

  • Salicylate Intoxication in the Elderly
    Drugs & Aging, 1992
    Co-Authors: Chester Durnas, Barry J. Cusack
    Abstract:

    Aspirin (acetylsalicylic acid) and its Salicylate derivatives are effective antipyretic, analgesic, and anti-inflammatory agents that are still very widely used by the elderly despite the advent of newer, potentially safer nonsteroidal anti-inflammatory drugs (NSAIDs). However, none of the new NSAIDs have been proven to be more effective than aspirin or salicylic acid. Chronic Salicylate intoxication which is most common in the elderly, may occur with therapeutic doses. Increased toxicity in older patients often appears due to inadvertent overdosage. Dual prescribing or additional use of nonprescription Salicylates are some causes of unwitting long term toxicity. According to some studies, systemic clearance of Salicylate (mainly by hepatic metabolism) is reduced with age, as is renal elimination. These changes are of increased importance in the elderly using high therapeutic doses of Salicylates when metabolism is saturated and more unchanged drug is available for renal excretion. In the face of renal impairment, the risk of toxicity is increased. The diagnosis of acute Salicylate intoxication generally does not pose diagnostic problems. Patients often present with a history of intentional overdose, with hyperventilation, fever, and nausea. The diagnosis can be confirmed by measuring serum Salicylate concentrations. Chronic intoxication often poses a diagnostic dilemma with atypical presentations mimicking other disease states such as diabetic ketoacidosis, delirium, cerebrovascular accident, myocardial infarction or cardiac failure. The diagnosis of Salicylate intoxication should be borne in mind when an older patient presents with recent deterioration in acitivities of daily living with no known cause. Plasma Salicylate concentrations should be measured if Salicylate intoxication is suspected, even if there is no documented history of Salicylate ingestion. The risk of Salicylate nephrotoxicity is also increased with age, and upper gastrointestinal haemorrhage is associated with increased mortality in older age groups. Treatment of acute toxicity consists of prompt recognition of Salicylate intoxication, use of activated charcoal, correction of acid-base abnormalities, general supportive measures, and if concentrations are extremely high, dialysis can be effectively used. Chronic toxicity, which can occur even with marginally high Salicylate concentrations, is treated with drug withdrawal and supportive therapy. Chronic Salicylate toxicity can be averted by prescription of conservative doses of drug, avoidance of concomitant use of different Salicylate preparations, and therapeutic monitoring to guide dosage. Renal function should be monitored to detect nephrotoxicity from chronic Salicylate therapy. Patients should be regularly screened for evidence of gastrointestinal bleeding. Use of aspirin and other NSAIDs should be avoided, if possible, in older patients with a history of upper gastrointestinal haemorrhage. If aspirin therapy is required, misoprostol prophylaxis can be employed.